78570
D-(-)-α-苯基甘氨酸
puriss., ≥99.0% (NT)
别名:
(R)-(-)-α-氨基苯基乙酸
等级
puriss.
方案
≥99.0% (NT)
旋光性
[α]20/D −156±2°, c = 1% in 1 M HCl
灼烧残渣
≤0.05%
mp
≥300 °C (dec.)
应用
peptide synthesis
SMILES字符串
N[C@@H](C(O)=O)c1ccccc1
InChI
1S/C8H9NO2/c9-7(8(10)11)6-4-2-1-3-5-6/h1-5,7H,9H2,(H,10,11)/t7-/m1/s1
InChI key
ZGUNAGUHMKGQNY-SSDOTTSWSA-N
正在寻找类似产品? 访问 产品对比指南
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
302.0 °F - closed cup
闪点(°C)
150 °C - closed cup
个人防护装备
Eyeshields, Gloves, type N95 (US)
法规信息
新产品
此项目有
José Alixandre de Sousa Luis et al.
Molecules (Basel, Switzerland), 15(1), 128-137 (2010-01-30)
Hydantoins and their derivatives constitute a group of pharmaceutical compounds with anticonvulsant and antiarrhythmic properties, and are also used against diabetes. N-3 and C-5 substituted imidazolidines are examples of such products. As such, we have developed a synthesis of 2,4-dione
Ulrike Müller et al.
Metabolic engineering, 8(3), 196-208 (2006-02-10)
D-phenylglycine (D-Phg) is an important side chain building block for semi-synthetic penicillins and cephalosporins such as ampicillin and cephalexin. To produce d-Phg ultimately from glucose, metabolic engineering was applied. Starting from phenylpyruvate, which is the direct precursor of L-phenylalanine, an
James J Lynch et al.
Pain, 125(1-2), 136-142 (2006-06-20)
Gabapentin and pregabalin have been demonstrated, both in animal pain models and clinically, to be effective analgesics particularly for the treatment of neuropathic pain. The precise mechanism of action for these two drugs is unknown, but they are generally believed
Shohei Tashiro et al.
Inorganic chemistry, 50(1), 4-6 (2010-12-01)
The optically active cobalt(III) complex with chiral cyclen, (2S,5S,8S,11S)-2,5,8,11-tetraethyl-1,4,7,10-tetraazacyclododecane, preferentially binds to D-phenylglycine (D-Phg) or D-t-leucine (D-t-Leu) rather than L-Phg or L-t-Leu, respectively, with 20% de in dimethyl sulfoxide at 293 K. Comparative studies on the crystal structures of cobalt(III)
Katrin Groebke Zbinden et al.
Bioorganic & medicinal chemistry letters, 15(23), 5344-5352 (2005-10-11)
We describe the structure-based design and synthesis of highly potent, orally bioavailable tissue factor/factor VIIa inhibitors which interfere with the coagulation cascade by selective inhibition of the extrinsic pathway.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持